tetano
Editor, Senior Moderator
Nat Commun
. 2022 Jul 19;13(1):4182.
doi: 10.1038/s41467-022-31557-0.
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Anahita Fathi[SUP] 1 2 3 4 [/SUP], Christine Dahlke[SUP] 1 2 3 [/SUP], Verena Krähling[SUP] 5 6 [/SUP], Alexandra Kupke[SUP] 5 6 [/SUP], Nisreen M A Okba[SUP] 7 [/SUP], Matthijs P Raadsen[SUP] 7 [/SUP], Jasmin Heidepriem[SUP] 8 [/SUP], Marcel A Müller[SUP] 9 10 [/SUP], Grigori Paris[SUP] 8 [/SUP], Susan Lassen[SUP] 1 2 3 [/SUP], Michael Klüver[SUP] 5 6 [/SUP], Asisa Volz[SUP] 11 12 [/SUP], Till Koch[SUP] 2 3 4 [/SUP], My L Ly[SUP] 1 2 3 [/SUP], Monika Friedrich[SUP] 1 2 3 [/SUP], Robert Fux[SUP] 13 14 [/SUP], Alina Tscherne[SUP] 13 14 [/SUP], Georgia Kalodimou[SUP] 13 14 [/SUP], Stefan Schmiedel[SUP] 3 4 [/SUP], Victor M Corman[SUP] 9 10 [/SUP], Thomas Hesterkamp[SUP] 15 [/SUP], Christian Drosten[SUP] 9 10 [/SUP], Felix F Loeffler[SUP] 8 [/SUP], Bart L Haagmans[SUP] 7 [/SUP], Gerd Sutter[SUP] 13 14 [/SUP], Stephan Becker[SUP] 5 6 [/SUP], Marylyn M Addo[SUP] 16 17 18 [/SUP]
Affiliations
Abstract
Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate the safety (primary objective) and immunogenicity (secondary and exploratory objectives: magnitude and characterization of vaccine-induced humoral responses) of a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. MVA-MERS-S booster vaccination is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n = 1) and the S2 subunit (n = 3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials. Trial registration: Clinicaltrials.gov NCT03615911.
. 2022 Jul 19;13(1):4182.
doi: 10.1038/s41467-022-31557-0.
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Anahita Fathi[SUP] 1 2 3 4 [/SUP], Christine Dahlke[SUP] 1 2 3 [/SUP], Verena Krähling[SUP] 5 6 [/SUP], Alexandra Kupke[SUP] 5 6 [/SUP], Nisreen M A Okba[SUP] 7 [/SUP], Matthijs P Raadsen[SUP] 7 [/SUP], Jasmin Heidepriem[SUP] 8 [/SUP], Marcel A Müller[SUP] 9 10 [/SUP], Grigori Paris[SUP] 8 [/SUP], Susan Lassen[SUP] 1 2 3 [/SUP], Michael Klüver[SUP] 5 6 [/SUP], Asisa Volz[SUP] 11 12 [/SUP], Till Koch[SUP] 2 3 4 [/SUP], My L Ly[SUP] 1 2 3 [/SUP], Monika Friedrich[SUP] 1 2 3 [/SUP], Robert Fux[SUP] 13 14 [/SUP], Alina Tscherne[SUP] 13 14 [/SUP], Georgia Kalodimou[SUP] 13 14 [/SUP], Stefan Schmiedel[SUP] 3 4 [/SUP], Victor M Corman[SUP] 9 10 [/SUP], Thomas Hesterkamp[SUP] 15 [/SUP], Christian Drosten[SUP] 9 10 [/SUP], Felix F Loeffler[SUP] 8 [/SUP], Bart L Haagmans[SUP] 7 [/SUP], Gerd Sutter[SUP] 13 14 [/SUP], Stephan Becker[SUP] 5 6 [/SUP], Marylyn M Addo[SUP] 16 17 18 [/SUP]
Affiliations
- PMID: 35853863
- DOI: 10.1038/s41467-022-31557-0
Abstract
Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate the safety (primary objective) and immunogenicity (secondary and exploratory objectives: magnitude and characterization of vaccine-induced humoral responses) of a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. MVA-MERS-S booster vaccination is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n = 1) and the S2 subunit (n = 3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials. Trial registration: Clinicaltrials.gov NCT03615911.